Johnson & Johnson to Acquire V-Wave
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
August 20, 2024 8:40 AM EDT(Updated - August 20, 2024 11:13 AM EDT)
Johnson & Johnson (NYSE: JNJ) announced Tuesday that it has struck an agreement to acquire V-Wave Ltd., a privately-held company specializing in treatments for heart failure.
The deal will see Johnson & Johnson make an upfront payment of $600 million, with the potential for an additional $1.1 billion in milestone payments.
V-Wave will join Johnson &... More
Johnson & Johnson gets green light for lung cancer combination treatment
August 20, 2024 7:49 AM EDTJohnson & Johnson (NYSE: JNJ) announced Tuesday that it has received U.S. Food and Drug Administration (FDA) approval for a combination treatment of RYBREVANT and LAZCLUZE for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.
According to the company, it... More
